Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.

Analysts fell to the sidelines weighing in on Revvity (RVTY – Research Report) and Intra-Cellular Therapies (ITCI – Research Report) with ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...

UnitedHealth Group's headquarters building is seen in Minnetonka, Minnesota, U.S. in this handout picture taken in 2019. UnitedHealth Group/Handout via REUTERS/File Photo Analysts and investors ...

Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...

Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

Neuren Pharmaceuticals (11.54%) — Recouped all losses from Wednesday’s selloff after it finished as the worst performer ...